SEC Comment Letter 0000000000-25-001365 to Indaptus Therapeutics, Inc. (INDP)
Indaptus Therapeutics, Inc.
Date: Feb. 7, 2025 · CIK: 0001857044 · Accession: 0000000000-25-001365
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-284707
Letter
February 7, 2025 Jeffrey Meckler Chief Executive Officer Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York, NY 10019 Re:Indaptus Therapeutics, Inc. Registration Statement on Form S-3 Filed February 5, 2025 File No. 333-284707 Dear Jeffrey Meckler: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Gary M. Emmanuel, Esq.
Show Raw Text
February 7, 2025
Jeffrey Meckler
Chief Executive Officer
Indaptus Therapeutics, Inc.
3 Columbus Circle, 15th Floor
New York, NY 10019
Re:Indaptus Therapeutics, Inc.
Registration Statement on Form S-3
Filed February 5, 2025
File No. 333-284707
Dear Jeffrey Meckler:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Gary M. Emmanuel, Esq.